Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease: Short-Term Pain for Long-Term Gain

Charles J Ferro; Jonathan N Townend

doi:10.1016/j.jacc.2024.04.013

Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease: Short-Term Pain for Long-Term Gain

J Am Coll Cardiol. 2024 Jun 18;83(24):2437-2439. doi: 10.1016/j.jacc.2024.04.013. Epub 2024 May 12.

Authors

Charles J Ferro¹, Jonathan N Townend²

Affiliations

¹ Birmingham Cardiorenal Research Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom. Electronic address: charles.ferro@uhb.nhs.uk.
² Birmingham Cardiorenal Research Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.

PMID: 38739066
DOI: 10.1016/j.jacc.2024.04.013

No abstract available

Keywords: acute kidney injury; chronic kidney disease; eplerenone; heart failure with reduced ejection fraction; mineralocorticoid receptor antagonist; spironolactone.

Publication types

Editorial

MeSH terms

Heart Failure* / drug therapy
Humans
Mineralocorticoid Receptor Antagonists* / therapeutic use
Renal Insufficiency, Chronic* / complications

Substances

Mineralocorticoid Receptor Antagonists